Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of Fair Value Measurements

			Fair Value Measurement Using
	Carrying Value		Level 1		Level 2		Level 3		Total
Investments in Equity Securities
Adhera Therapeutics – Convertible Series E Preferred Shares	$	1,769,300	$	-	$	-	$	1,769,300	$	1,769,300
	$	1,769,300	$	-	$	-	$	1,769,300	$	1,769,300

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following number of shares have been excluded from diluted loss since such inclusion would be anti-dilutive:

	Six months ended
	June 30, 2019		June 30, 2018
Convertible notes		8,000,000		-
Stock options		6,477,922		7,319,000
Warrants		22,216,211		24,528,000
Potentially dilutive securities		36,694,133		31,847,000

	Three months ended
	June 30, 2019		June 30, 2018
Convertible notes		8,000,000		-
Stock options		6,477,922		545,000
Warrants		22,216,211		2,312,000
Potentially dilutive securities		36,694,133		2,857,000